Expertise Partners


Agilent Technologies is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward advancing the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. By partnering with Agilent for your CDx development, your drug development program will reap the benefits of an innovative industry leader with more than 20 years’ experience. Agilent launched the first FDA-approved companion diagnostic and continues to deliver world-class CDx products in close collaboration with our pharma partners.

Apis Assay Technologies Ltd. is leveraging the transformational power of systems biology, innovative synthetic antibody technologies, and genomic big data to directly address the historical failures of translating biomarkers into clinical utility.

Operating under an ISO 13485 QMS Apis seeks to develop and manufacture proprietary and client derived disease- and tissue-agnostic biomarkers as IVD tests (MDx, CDx and CoDx), maximising the benefit to both patients and stakeholders in either a centralised or de-centralised laboratory setting.


Guardant Health is a pioneer in non-invasive cancer diagnostics, addressing challenges across the cancer care continuum. The company has raised more than $200 million from leading venture capital firms and in 2014 launched Guardant360, the first comprehensive liquid biopsy for clinical use. Guardant Health is improving therapy selection for advanced cancer patients across the globe using its proprietary cell-free circulating tumor DNA NGS platform. Guardant Health is partnered with biopharmaceutical companies to prospectively screen patients for trial enrollment, develop companion diagnostics to support clinical adoption, and use retrospective analysis for early insights into patient response and tumor evolution, as well as accelerate the development of new therapies.


NeoGenomics is an industry-leading cancer diagnostics and pharma services company. We enable advanced oncology patient care leveraging the most extensive diagnostic solid tumor and hematological test menus, sub-specialty pathology, and expertise in biomarker development. We partner closely with our pharma and research clients to meet program objectives and delivery across our global laboratory sites (US, EU, APAC & China) from biomarker discovery through CDx validation and commercialization.

Illumina Logo

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Labcorp Oncology is committed to advancing cancer care by pioneering scientific breakthroughs, powering better decisions through actionable data-driven patient insights and bringing healthcare within reach for all cancer patients throughout their continuum of care. With our comprehensive, specialized diagnostic services and our drug development capabilities, Labcorp is uniquely positioned to support you, from discovery through post-marketing and commercialization—using a biomarker-driven strategy throughout the entire process. Learn more at:


Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We support precision medicine from translational research to the development of companion diagnostics with innovative technologies and service through our Thermo Scientific, Applied Biosystems, Invitrogen, Gibco and Ion Torrent brands.

q2 solutions

Q² Solutions is a leading global clinical trial laboratory services organization that provides comprehensive testing, project management, supply chain, biorepository, biospecimen, and consent tracking solutions. Leveraging our next generation technologies, we deliver agile and precise services designed to meet the diverse needs of our clients. We provide scientific expertise and innovative solutions for ADME, bioanalytical, genomics, vaccines, and central laboratory services, including flow cytometry, anatomic pathology, immunoassay, molecular, companion diagnostics and translational science, with meticulous regional and global clinical trial implementation support and high-quality data delivery. At Q² Solutions, our work is rooted in research, grounded in collaboration, and guided by our passion to turn the hope of patients  and caregivers around the world into the help they need.

Roche for website

With global headquarters located in Basel, Switzerland, Roche is a pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotechnology company and the world leader in vitro diagnostics and tissue-based cancer diagnostics. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche Diagnostics, a division of Roche, offers the industry’s most comprehensive in-vitro diagnostics solutions, covering molecular diagnostics, clinical chemistry and immunoassays, tissue diagnostics, point of care testing, patient self-testing, next-generation sequencing, laboratory automation and IT and decision support solutions. With its products and services, Roche Diagnostics supports healthcare providers in transforming data into actionable insights.


Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. Tempus offers companion diagnostic development across our portfolio of assays, leveraging a broad-panel, universal platform used by thousands of oncologists globally. These assays can each incorporate multiple companion diagnostic markers, providing value across biopharma portfolios.


As an expert in immune biomarkers, Veracyte's goal is to play a leading role in partnering with the academic and pharmaceutical industry to leverage the immune contexture concept and deliver practical routine diagnostic tools to significantly impact therapy prescription for the benefit of patients. By precisely measuring the immune reaction in and around the tumor, Veracyte helps clinicians to determine the degree of severity of a patient’s disease and predict the response to treatment, regardless of the cancer stage or the molecular class.

Program Partners


Accelerate your next breakthrough in diagnostics and therapeutics. Abcam’s comprehensive portfolio of high quality, customizable solutions are ideal for diagnostic and therapeutic applications. Our technical ability coupled with a flexible commercial approach enables us to deliver projects that will help achieve your goals


Almac Diagnostics is a stratified medicine company specialising in biomarker driven clinical trials. Our diagnostic experience spans oncology, immunology, CNS and infective diseases. Our global laboratories, based in the UK and US offer tailored solutions from discovery to commercialisation: Biomarker discovery. Custom assay development & validation. DNA and RNA panel solutions. Flexible CDx development & commercialisation. Expert regulatory support. Bioinformatics & software development. Your Clinical Trial Diagnostic Partner.


Aignostics is a spin-off from Charité Berlin, Europe’s largest university hospital, specialising in AI-powered pathology generating novel algorithms, often built on own data, to deliver valuable insights to our clients. Insights which culminate into enhanced understanding of biology of disease such as novel biomarkers/target ID and drug response characteristics. Our proprietary technology has delivered state-of-the-art performance, with algorithms that can be implemented into clinical trials and pulled through into routine diagnostics to improve patient treatment.


Medical diagnostic reporting of surgical pathology specimens as part of public sector health care system in the UK (NHS).

Bio-Techne Companion Diagnostics delivers precision medicine services spanning the continuum from biomarker discovery to post-market commercialization of a CDx product. We bring a 20+ year track record of success including the development of over 2700 assays for 570 targets, with over 50 clinical tests built for pharma and 15 CLIA tests. Our multi-omic, platform-agnostic approach, paired with clinical trial sample testing readiness at our CLIA labs and international regulatory expertise, allows us to offer customizable solutions so that a pharma partner can deliver novel treatments to the patients most likely to benefit, faster.

Burning Rock

Burning Rock Dx specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. With the unique capability and experience in global trials, we are looking for partnerships to advance the field of companion diagnostics in order to achieve better patient outcomes.


Leica Biosystems is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. In line with our Mission, we have established the following challenge for ourselves: Enable patients to get their diagnosis within 24 hours from biopsy. This is a goal we are striving towards, a goal that will guide our future strategies. This vision aims to decrease the time it takes from biopsy to patient diagnosis, to a 24 hour period. With a presence in every step of the workflow, no other company is positioned to streamline all these steps so that the whole process takes less than 24 hours.


Medable's mission is to get effective therapies to patients faster. We provide an end-to-end, global cloud platform with a flexible suite of tools that allows sponsors, patients, providers & CRO's to work together as a team in clinical trials. Our solutions enable more efficient clinical research, more effective healthcare delivery, and more accurate precision and predictive medicine.

Our vision is to accelerate the path to human discovery and medical cures. We are passionate about driving innovation and empowering consumers. We are proactive, collaborative, self-motivated learners, committed, bold and tenacious. We are dedicated to making this world a healthier place


NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company provides three platforms that allow researchers to map the universe of biology. The nCounter® Analysis System, cited in more than 5,900 peer-reviewed publications, offers a way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. NanoString’s GeoMx® Digital Spatial Profiler enables highly multiplexed spatial profiling of RNA and protein targets in various sample types, including FFPE tissue sections, and has been cited in more than 75 peer-reviewed publications. The CosMx Spatial Molecular Imager, with commercial availability expected in 2022, enables highly sensitive, high-resolution imaging of hundreds to thousands of RNAs or proteins directly from single cells within morphologically intact whole tissue sections. For more information, visit


Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera's tumor-informed assay is optimized to detect low levels of ctDNA with high accuracy in identifying MRD and predicting recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types. The test is available for clinical and research use, has been designated by the FDA as a Breakthrough Device, received CE mark. Look deeper at:

NuProbe Logo

NuProbe is a cutting-edge genomics and molecular diagnostics company with revolutionary molecular technologies to improve the sensitivity of sequencing mutations and copy number variations by over 10-fold. NuProbe has sites in Houston, USA, Shanghai, China and Suzhou, China. NuProbe’s vision is to offer affordable, timely, and accurate disease state information to enable precision medicine and improve patient outcomes.


Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the naica® system. Taking advantage of cutting-edge microfluidic innovations, Stilla® aims to make dPCR a lab commodity in all Life Sciences areas: research, therapeutics, and all the “omics”. Learn more about Stilla Technologies:


Ultivue is a venture-backed company developing reagent-driven solutions for high-performance biological imaging in situ, combining unlimited multiplexing at high speed with high spatial resolution. Ultivue’s proprietary solutions will enable researchers to realize the promise of personalized medicine. The company has launched products and services that will seamlessly integrate into existing workflows for biomarker discovery, assay validation, and companion diagnostic applications.

MicrosoftTeams-image (1)

Veranex brings together best-in-class expertise in product design and engineering, medical device evaluation, clinical development, data management, regulatory, and market access to deliver an integrated and comprehensive solution from concept to commercial success. Our product designers, engineers, market strategists, regulatory professionals, health economists, and clinical development experts help you develop products that deliver sustained value. We partner with you to overcome market and business challenges to ensure your success. With 30+ years of medical product development and commercialization expertise, we have the knowledge and integrated processes to speed you from idea to launch.

Panel Partners


BD Biosciences produces research and clinical tools for the study of single cells to better understand infectious diseases, immunological disorders and cancers. That information can aid in the discovery and development of new drugs and vaccines and the diagnosis and management of diseases, including the development of biomarkers and CDx.  Products include the BD FACSLyric™ Flow Cytometer (RUO/IVD), BD FACSDuetTM Sample Preparation System, BD FACSymphony™ A5 Cell Analyzer and S6 Cell Sorter, BD Rhapsody™ Single-Cell Analysis System for multiomics, a comprehensive reagent portfolio (RUO/IVD), and informatics solutions with BD FlowJo™ Software.  More solutions. More answers. More data you can trust. Discover more with BD at your side.

logo-horizontal (3)

PathAI is a leading provider of AI-powered research tools and services for pathology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning. Based in Boston, PathAI works with leading life sciences companies and researchers to advance precision medicine.

To learn more, visit

Spotlight Partners

Genomenon Logo 2021 - stacked tag-28 (1) (002)

Genomenon provides immediate insight into the published genomic research for every disease, gene, and mutation found in the scientific literature. Pharmaceutical and biotech companies license Genomenon’s comprehensive genomic landscape on any given disease to identify and prioritize genomic biomarkers for drug discovery and clinical trial targets

panakeia logo

Panakeia provides comprehensive ‘omics' molecular analysis of patient tissues significantly faster and cheaper than other methods. We are creating AI-technology to provide biomarker information directly from H&E-stained tissue images. Panakeia offers reliable results in minutes rather than executing multiple physical tests over several days or weeks. Our offerings enhance both clinical diagnostics and drug development.

sight therapeutics logo

The faster we diagnose, the faster we can treat. At Sight Diagnostics, we aim to improve health through fast, accurate and convenient diagnostic testing. Sight’s latest analyzer, Sight OLO, performs a Complete Blood Count, the most commonly ordered blood test, in minutes, not hours. It’s compact: designed to be used by anyone, anywhere. Sight’s method, developed over a decade of research, represents a step-change in diagnostic technology. Our analyzers create a digital version of your blood, by capturing 1,000 highly detailed images of a finger prick sample, which is then interpreted by our proprietary algorithms. These images could offer valuable insights into blood cell morphology to aid in biomarker, drug development and precision medicine initiatives. Partner with Sight today to reimagine diagnostics for the AI era.


SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory, and biopharma institutions globally.

Meeting & Exhibitor Partners


Indivumed is a physician-led, integrated global oncology company committed to unveiling complex mechanisms of cancer, in order to support precision oncology. Only a multi-omics approach can achieve this goal – and reliable multi-omics require especially high-quality biospecimens and data.

Through its three divisions, IndivuServ, IndivuType, and IndivuTest, Indivumed offers specialized products and services that support customers in biomarker and target discovery, drug development, clinical trials, individualized therapy and more.


Randox Biosciences is devoted to advancing scientific discovery, drug development and diagnostics.

Spanning four key divisions; Life Sciences, Pharma Sciences, Clinical Laboratories, Research and Molecular; Randox Biosciences offers complete tailored solutions for clinical and research use. From initial assay development, through to providing companion diagnostics, molecular and custom based assays across a range of therapy areas.

Pharmaceutical and biotech companies are increasingly investing in the research and development of new therapies to address the world’s growing need for earlier and more effective patient treatment. This demand has caused the pace of innovation in drug development, manufacture, and delivery to accelerate rapidly. As an established IVD company, we offer tailored diagnostic solutions to support faster, more effective and safe development of new drugs. We have a wide range of in-house capabilities, ranging from the selection and patenting of novel Biomarkers; manufacture of bio reagents; production of single and multiplex IVD grade tests; quality control; provision of clinical laboratory services; regulatory expertise and worldwide distribution. Randox Biosciences are your trusted diagnostic partner to achieve precise results, enabling informed treatment decisions.

At Randox we can provide Next Generation Sequencing (NGS) and analysis, Genotyping, Proteomics and qPCR/ targeted genotyping solutions and services. Studying our genome can help us understand our risk of developing certain conditions, predicting our response to particular drugs/foods/treatments, and help with the development of new treatments for different health conditions. Randox has its own Computational Genetics Team consisting of data analysts and bioinformaticians which have built custom pipelines for pathogen sequencing and are subsequently ran on our powerful servers to provide the most high quality services.


HTG is the leading provider of whole transcriptome NGS services and systems that uniquely leverage ultra-efficient gene expression profiling to deliver fast and reliable data so you can expand frontiers in RNA discovery.


"Fulgent Genetics Inc. is a global CLIA-certified and CAP-accredited laboratory offering comprehensive clinical and Pharma services, specializing in oncology and rare diseases."

SeromYx Systems cmyk

SeromYx is a specialist in correlating antibody function and clinical outcome.  Our broad panel of high throughput and robust assays coupled to machine learning provides unique biomarker insights to support drug discovery and development along the value chain.  To learn more, please visit our exhibition space in the networking area or